Literature DB >> 26722300

Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-κB in oral squamous cell carcinoma.

Eun-Young Lee1, Ji-Yeon Kang2, Kyoung-Won Kim1.   

Abstract

Tumor development and progression are multistep processes that involve local tumor growth and invasion, followed by metastasis. The aggressiveness of the tumor is the major determinant of the mortality of oral cancer patients. The present study investigates whether the expression levels of cyclooxygenase-2 (COX-2), nuclear factor-κB (NF-κB), peroxiredoxin 1 (PRDX1) and PRDX6 are associated with the development, proliferation, differentiation and recurrence of oral squamous cell carcinoma (OSCC). The mRNA expression levels of COX-2, NF-κB, PRDX1 and PRDX6 were examined in 50 OSCC specimens and 19 normal oral mucosae by quantitative polymerase chain reaction (qPCR). qPCR analysis showed that the mRNA levels of COX-2 in OSCC were significantly higher than those in the normal oral mucosae (P=0.021). The expression levels of PRDX1 in high-stage tumors (T3 and T4) were significantly elevated compared with those in low-stage tumors (T1) (P=0.047). Additionally, the expression levels of NF-κB in the high-grade tumor were significantly elevated compared with those in the low-grade tumors (P=0.030). Overall, it was indicated that the expression of COX-2 is strongly associated with the development of OSCC. Moreover, the enhanced expression of PRDX1 and NF-κB may function in the progression of OSCC, which serves as a useful marker for prognosis in patients with oral cancer.

Entities:  

Keywords:  cyclooxygenase-2; nuclear factor-κB; oral squamous cell carcinoma; peroxiredoxin 6; peroxiredoxin I; polymerase chain reaction

Year:  2015        PMID: 26722300      PMCID: PMC4665682          DOI: 10.3892/ol.2015.3705

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  43 in total

1.  High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity.

Authors:  H Nakayama; T Ikebe; M Beppu; K Shirasuna
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

2.  Augmented expression of peroxiredoxin I in lung cancer.

Authors:  J W Chang; H B Jeon; J H Lee; J S Yoo; J S Chun; J H Kim; Y J Yoo
Journal:  Biochem Biophys Res Commun       Date:  2001-11-30       Impact factor: 3.575

3.  Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.

Authors:  Caren C Bancroft; Zhong Chen; Jason Yeh; John B Sunwoo; Ning T Yeh; Sadhana Jackson; Chad Jackson; Carter Van Waes
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

4.  The pag gene product, a physiological inhibitor of c-abl tyrosine kinase, is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress.

Authors:  M T Prospéri; D Ferbus; D Rouillard; G Goubin
Journal:  FEBS Lett       Date:  1998-02-13       Impact factor: 4.124

5.  Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance.

Authors:  Masami Shibata; Isamu Kodani; Mitsuhiko Osaki; Kunio Araki; Hironobu Adachi; Kazuo Ryoke; Hisao Ito
Journal:  Oral Oncol       Date:  2005-03       Impact factor: 5.337

6.  A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins.

Authors:  M T Prospéri; D Ferbus; I Karczinski; G Goubin
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

7.  Peroxiredoxins, a novel protein family in lung cancer.

Authors:  Siri T Lehtonen; Anne-Mari Svensk; Ylermi Soini; Paavo Pääkkö; Pasi Hirvikoski; Sang Won Kang; Marjaana Säily; Vuokko L Kinnula
Journal:  Int J Cancer       Date:  2004-09-10       Impact factor: 7.396

Review 8.  Structure, mechanism and regulation of peroxiredoxins.

Authors:  Zachary A Wood; Ewald Schröder; J Robin Harris; Leslie B Poole
Journal:  Trends Biochem Sci       Date:  2003-01       Impact factor: 13.807

9.  Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer.

Authors:  Changyi Quan; Eun-Jong Cha; Hyung-Lae Lee; Kwang Hee Han; Keon Myung Lee; Wun-Jae Kim
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

10.  Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis.

Authors:  Yasunari Takada; Sujay Singh; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2004-01-07       Impact factor: 5.157

View more
  6 in total

1.  Nrf2-peroxiredoxin I axis in polymorphous adenocarcinoma is associated with low matrix metalloproteinase 2 level.

Authors:  J M Brod; Ana Paula Dias Demasi; V A Montalli; L N Teixeira; C Furuse; M C Aguiar; A B Soares; M Sperandio; V C Araujo
Journal:  Virchows Arch       Date:  2017-08-28       Impact factor: 4.064

2.  SIGNET: single-cell RNA-seq-based gene regulatory network prediction using multiple-layer perceptron bagging.

Authors:  Qinhuan Luo; Yongzhen Yu; Xun Lan
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

3.  Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.

Authors:  Jefferson da Rocha Tenório; Leorik Pereira da Silva; Marília Gabriela de Aguiar Xavier; Thalita Santana; George João Ferreira do Nascimento; Ana Paula Veras Sobral
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-07-12       Impact factor: 2.503

Review 4.  Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines.

Authors:  Zhe Sun; Xiaodong Sun; Zhanwei Chen; Juan Du; Yihua Wu
Journal:  Int J Pept Res Ther       Date:  2021-12-08       Impact factor: 1.931

5.  Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma.

Authors:  Yajun Shen; Haoyue Xu; Lingyu Li; Yunping Lu; Min Zhang; Xin Huang; Xiaofei Tang
Journal:  Cancer Manag Res       Date:  2021-07-15       Impact factor: 3.989

6.  The prognostic values of the peroxiredoxins family in ovarian cancer.

Authors:  Saisai Li; Xiaoli Hu; Miaomiao Ye; Xueqiong Zhu
Journal:  Biosci Rep       Date:  2018-09-05       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.